A 5‐decade analysis of 13,715 carcinoid tumors
By I. Modlin, K. Lye, M. Kidd. Cancer, 2003
2,750 citations recorded by the source corpus.
Subfields: Epidemiology, Oncology, Surgery
View Paper: https://www.semanticscholar.org/paper/7451677570d1445e384147ac638a3bd249a338ec
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Oncology
In Surgery
Citations in the corpus
- Exploring the rising incidence of neuroendocrine tumors: A population‐based analysis of epidemiology, metastatic presentation, and outcomes (2015, methodology): “The epidemiology of NETs has been examined in previous national and regional registries, with the largest ones using SEER and Norway National Cancer Registry data.(1,3,10) Although the increase in the incidence of NETs appears consistent among studies,(1,11,22) the magnitude of the change that we ar”
- TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system (2007, background): “Given their rarity [10, 14–17], correct diagnosis and appropriate treatment are often difficult in nonexpert settings and even for appendiceal “carcinoids,” probably the best known GEP-NETs with the most benign behavior [31].”
- Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. (2008, methodology): “Despite their reputation for being rare, recent analyses from the Surveillance, Epidemiology, and End Results Program database suggest that the diagnosed incidence of LGNETs is rising.(5) Mammalian target of rapamycin (mTOR) is a conserved serine/threonine kinase that regulates the cell cycle and me”
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors (2017, neutral): “Nausea 65 (59) 4 (4) 13 (12) 2 (2) <0.”
- Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. (2015, background): “This tendency of PCs to increase over time is likely due to improved awareness [25, 26] and increased use of special immunohistochemistry (IHC) stains [14, 16, 21, 27].”
- Carcinoid Tumors (2008, background): “Presumed to arise from the intraepithelial endocrine cells disseminated throughout the intestine, small bowel carcinoids most commonly occur in the distal ileum within 60 cm of the ileocecal valve [11,13]; moreover, the incidence of these tumors increases with proximity to the cecum.”
- Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs) (2005, background): “Moreover, it appears that up tow20% of patients with gastric NETs may also develop another synchronous cancer, typically affecting the gastrointestinal tract.(12) There are insufficient data to know whether this is a feature in patients with other NETs.”
- Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. (2008, background): “5 in 100,000 population per year and approximately one in 100,000 population per year, respectively.(1-8) However, since 5-year survival rates in patients with GEPNETs, irrespective of stage of disease, are over 60%,(5,8-11) their prevalence is much higher.”
- Epigenetics: The Science of Change (2006, background): “As gastroenteropancreatic NETs are rare [9, 13, 14], it is tempting to lump them together and equate all digestive “carcinoids” with the appendiceal “carcinoid,” probably the best known NET with the most benign behavior [28].”